rchestrated.bio

DrugAdopt · Case study

Tolvaptan in ADPKD

One finding, traced from the report to the code behind it. Read the full report.

One finding

What changed downstream of tolvaptan’s target?

Tolvaptan blocks the V2 receptor in the kidney’s water-handling pathway. We reanalyzed public kidney-expression data from 12 treated and 12 untreated male Pkd1-knockout mice selected for expression profiling.

Aqp2 RNA was lower in treated mouse kidneys. Aqp2 encodes a water channel downstream of V2 signaling. This exploratory result adds a molecular signal to investigate alongside cyst-fluid secretion and the clinical kidney-volume findings.

Eight exploratory marker probes in mouse kidneys. Dots show tolvaptan-minus-untreated RNA differences, and bars show 95 percent confidence intervals.
Exploratory mouse analysis. Dots show RNA differences; bars show 95% confidence intervals. Report §2.1.7
01

Report

Mouse expression analysis

Aqp2 encodes aquaporin-2, a water channel, while Avpr2 encodes the receptor itself.

The Aqp2 probe showed a −0.4017 log2 difference between treated and untreated kidneys.

Exploratory comparison of selected whole-kidney samples.

03

Spreadsheet

Aqp2 · probe 17314833

MeasureValue
RNA difference−0.4017
log2 units
95% confidence interval−0.5719 to −0.2314
Adjusted P value0.000218

Tolvaptan minus untreated. P values use Benjamini–Hochberg adjustment.

Discuss your project

Image detail